DBV Technologies (NASDAQ:DBVT) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.
Valuation and Earnings
This table compares DBV Technologies and bluebird bio's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
DBV Technologies | $14.75 million | 37.39 | $-172,020,000.00 | ($2.33) | -2.15 |
bluebird bio | $44.67 million | 42.00 | $-789,610,000.00 | ($14.31) | -1.95 |
DBV Technologies has higher earnings, but lower revenue than bluebird bio. DBV Technologies is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for DBV Technologies and bluebird bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
DBV Technologies | 2 | 4 | 3 | 0 | 2.11 |
bluebird bio | 0 | 13 | 4 | 0 | 2.24 |
DBV Technologies presently has a consensus target price of $7.0714, indicating a potential upside of 40.87%. bluebird bio has a consensus target price of $68.4667, indicating a potential upside of 145.05%. Given bluebird bio's stronger consensus rating and higher probable upside, analysts plainly believe bluebird bio is more favorable than DBV Technologies.
Profitability
This table compares DBV Technologies and bluebird bio's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
DBV Technologies | N/A | N/A | N/A |
bluebird bio | -256.84% | -45.78% | -35.14% |
Institutional and Insider Ownership
32.5% of DBV Technologies shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 15.3% of DBV Technologies shares are held by insiders. Comparatively, 3.6% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
DBV Technologies has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500.
Summary
DBV Technologies beats bluebird bio on 8 of the 14 factors compared between the two stocks.